Oxford starts infant vaccine testing in stages to contain pandemic

Sign up here to receive our daily coronavirus newsletter on what you need to know and subscribe to our Covid-19 podcast for the latest news and reviews.

The University of Oxford will begin testing the Covid-19 vaccine developed with AstraZeneca Plc in children, a potentially important step in ending the global pandemic.

The Oxford study plans to enroll 300 children aged 6 to 17, the university said in a statement on Saturday. The first vaccinations will take place this month, with up to 240 children receiving the coronavirus vaccine and the remainder a meningitis vaccine, which is expected to produce similar side effects. A larger study involving thousands of children is expected to be conducted by Astra in the United States later.

The phase II study will be conducted in Oxford and three UK cities – London, Southampton and Bristol – and will assess the safety and immune responses in children. Researchers will test the shot on children aged 12 to 17 years old before moving to the younger age group, with the initial data expected for the summer, Andrew Pollard, the lead investigator for the trial, said in an interview with Bloomberg.

The study will look at two dosing regimens one month and three months apart, said Pollard.

.Source